Laboratorios Farmaceuticos Rovi (ES:ROVI) has released an update.
Laboratorios Farmacéuticos ROVI has successfully passed all proposed resolutions during its Ordinary General Shareholders’ Meeting, including the approval of annual accounts, management reports, a dividend payout, and the re-election of board members and auditors for the upcoming year. Shareholders endorsed a dividend distribution equivalent to 35% of the 2023 consolidated profit, and confirmed KPMG Auditores, S.L. as the company’s auditors for 2024. The company will also implement a Long-Term Incentive Plan and a share capital reduction by amortizing its own shares.
For further insights into ES:ROVI stock, check out TipRanks’ Stock Analysis page.
